8-K: bioAffinity Technologies Announces Webinar on CyPath Lung Test

bioAffinity Technologies announced a Society for Advanced Bronchoscopy webinar to discuss the expanding role of its noninvasive CyPath Lung test in early-stage lung cancer detection and management.

Summary

• bioAffinity Technologies, Inc. announced that the Society for Advanced Bronchoscopy (SAB) will host a webinar on June 16, 2026, at 7 p.m. ET.
• The webinar, titled 'Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath Lung Testing,' will feature a multidisciplinary physician panel.
• Panelists will discuss the real-world benefits and integration of the CyPath Lung test into pulmonary, oncology, and surgical practices for early-stage lung cancer detection and management.
• CyPath Lung is a noninvasive test that uses automated flow cytometry and artificial intelligence to analyze the lung microenvironment for signs of malignancy.
• The test has demonstrated high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, particularly in patients with small indeterminate lung nodules.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, highlighting the potential of CyPath Lung and its integration into clinical practice through educational events, though commercialization and regulatory risks remain.

Positives

• The Society for Advanced Bronchoscopy (SAB) will host a webinar to discuss the expanding role of CyPath Lung in clinical practices.
• CyPath Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence.
• The webinar will feature a multidisciplinary physician panel including an interventional pulmonologist, a medical oncologist, and a thoracic surgeon.
• CyPath Lung has demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value (NPV) in a published clinical trial for high-risk patients with small indeterminate lung nodules.
• The high NPV of CyPath Lung can give physicians greater confidence in negative results, potentially sparing patients unnecessary invasive procedures.

Negatives

• CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool.
• The company faces risks related to the regulatory environment for laboratory developed tests and obtaining adequate reimbursement.

Risks

• The company's ability to successfully commercialize CyPath Lung.
• Risks related to the regulatory environment for laboratory developed tests.
• The company's ability to obtain and maintain adequate reimbursement for its products.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.

Future Outlook

The company is focused on the commercialization of CyPath Lung and faces risks related to regulatory environments, reimbursement, and general market uncertainties as outlined in its SEC filings.

Management Comments

• "We are seeing a significant increase in patients with indeterminate lung nodules as a result of expanded lung cancer screening and imaging for other conditions. When we consider not only prior smoking history but also an aging population, environmental and occupational exposures, and a better understanding of genetic predispositions, we recognize the real clinical challenges of managing this condition, of distinguishing between malignant and benign nodules."
• "Advanced navigational bronchoscopy serves as an accurate tool to diagnose lung cancer without major surgery, particularly in nodules greater than a centimeter. For smaller nodules, CyPath Lung complements bronchoscopy by helping to risk stratify and identify patients who should move forward with more invasive follow-up."
• "We are honored to collaborate with the Society for Advanced Bronchoscopy to provide clinicians with an opportunity to discuss innovative tools like CyPath Lung that support earlier intervention leading to better patient outcomes."

Industry Context

StockSavvy.ai notes that the focus on noninvasive diagnostics for early-stage lung cancer aligns with a broader industry trend towards less invasive procedures and the application of AI in medical diagnostics to improve accuracy and patient outcomes.

Comparison to Industry Standards

• The published clinical trial results for CyPath Lung (92% sensitivity, 87% specificity, 88% accuracy, 99% NPV) are competitive within the field of early-stage lung cancer detection, particularly for noninvasive methods.
• The use of automated flow cytometry and AI for analyzing the lung microenvironment represents an advancement in diagnostic technology, aiming to improve upon existing screening and diagnostic pathways.

Stakeholder Impact

• Shareholders may see increased interest in the company's technology and potential market adoption of CyPath Lung.
• Patients at high risk for lung cancer may benefit from a more accurate and less invasive diagnostic tool.
• Clinicians in pulmonary, oncology, and surgical practices will have access to information on integrating CyPath Lung into their diagnostic workflows.

Next Steps

• The Society for Advanced Bronchoscopy will host a webinar on June 16, 2026, to discuss CyPath Lung.
• The webinar will feature a multidisciplinary physician panel discussing the test's role in pulmonary, oncology, and surgical practices.

Key Dates

Keywords

lung cancer detection, CyPath Lung, noninvasive diagnostics, bioAffinity Technologies, pulmonary, oncology, thoracic surgery, webinar